The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with <i>KRAS</i> G12C Inhibitors in Preclinical Models

Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.